Drugs / E/C/F/TDF
last change Apr 2020 re-read 2 minutes ago

E/C/F/TDF

Developed for
HIV infectious disease

Trials 0

Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT01815736 Comparator Mar 2013 → Mar 2015 HIV infectious disease Gilead Sciences Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as E/C/F/TDF ClinicalTrials.gov intervention name — accepted as the source's own label NCT01815736
Route Oral “150/150/200/300 mg FDC tablet administered orally once daily” NCT01815736